Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

NCT03911973 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG: Gedatolisib
DRUG: Talazoparib

Sponsor

Kari Wisinski

Collaborators

[object Object]
[object Object]